Plaintiffs argue that companies like Novo Nordisk and Eli Lilly ignored clinical trial data, post-marketing surveillance, and adverse event reports that pointed to dangers such as stomach paralysis, intestinal obstruction, and permanent vision damage
In 2022, SAR441255 (GLP-1/GIP/glucagon receptor triagonist) was administered to obese, diabetic primates and healthy lean to overweight humans without diabetes
[DOI] [PubMed] 10.Luk T, et al
These drugs, like Wegovy (semaglutide) and Ozempic, help regulate blood sugar and insulin levels by mimicking the action of a natural hormone (GLP-1) in the body
For GLP-1 release, the article argues yes
TB500 influences intracellular actin availability, regulating cell motility, differentiation, and structural reorganization